This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Acute myelogenous leukemia (AML)

MDS1 and EVI1 complex locus (MECOM)

Cell-based and mouse studies suggest inhibiting MECOM could help treat AML. In bone marrow progenitor cells, myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX) fusion protein-induced transformation was lower in cells lacking a functional MECOM allele than in cells containing a functional MECOM allele. In mice, transplant of MECOM- leukemic cells decreased the development of AML symptoms compared with MECOM+ leukemic cells. Next steps include designing and synthesizing MECOM inhibitors and examining the role of MECOM in other cancers.

SciBX 6(41); doi:10.1038/scibx.2013.1155
Published online Oct. 24, 2013

Patent filed by the University of Rochester; available for licensing

Zhang, Y. et al. Blood; published online Sept. 10, 2013;
doi:10.1182/blood-2012-08-453662
Contact: Archibald S. Perkins, University of Rochester Medical Center, Rochester, N.Y.
e-mail:
archibald_perkins@urmc.rochester.edu